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ABO 부적합 신 이식 전 치료적 혈장교환술 횟수의 예측 변수로서의 
초기 ABO 항체 역가
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Initial ABO Antibody Titer as a Variable for Estimating Number of 
Therapeutic Plasma Exchange prior to ABO Incompatible Kidney 
Transplantation
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Background: Therapeutic plasma exchange (TPE) for desensitization in ABO incompatible kidney transplantation 
(KT) has raised concerns regarding efficiency and safety. The purpose of this study was to determine the number 
of TPE prior to KT required to reach target titer for KT according to ABO blood groups.
Methods: The distribution of ABO antibody (Ab) titer of 117 patients was investigated. The relationship between 
initial ABO Ab and number of TPEs required to reach target titer to ≤1:8 prior to KT was evaluated retrospectively 
according to blood groups and ABO Ab classes. 
Results: The initial IgG ABO Ab titers were the highest in blood O group recipients, and the average number± 
standard deviations (range) of TPEs performed prior to ABO incompatible KT was 3.0±1.1 (0∼5) in blood group 
A, 3.7±1.5 (0∼8) in blood group B, and 5.3±1.9 (2∼13) in blood group O, respectively. The best correlation 
was observed in the linear relationship between initial ABO Ab titer and number of TPEs required (y=0.6829x+ 
0.0523, R2=0.946, x=log2 initial ABO Ab titer, y=number of TPE required), regardless of the specific ABO blood 
group.
Conclusion: The number of TPEs can be highly deduced from initial ABO Ab titer and our developed equation 
in desensitization programs would help increase the efficiency of TPE and patient safety. (Korean J Blood Transfus 
2016;27:22-30)
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Introduction
ABO-incompatible kidney transplantation (iABO 
KT) has expanded the donor pool by increasing the 
availability of transplantable organs, decreasing the 
waiting period. The blood type barrier is a major ob-
stacle to the naturally occurring anti-A or anti-B, 
which cause hyperacute rejection in preliminary cas-
es, by not removing them from the circulation at the 
time of transplantation.1) Therapeutic plasma ex-
change (TPE) before an iABO KT may be used to 
prevent hyperacute rejection, and posttransplantation 
TPE is often used to treat antibody-mediated re-
jection that occurs in this setting.2)
Currently, most courses of desensitization include 
TPE followed by intravenous immunoglobulin (IVIG) 
as a preconditioning and medication of thymoglobu-
lin, tacrolimus, mycophenolate mofetil, and steroids 
as an immunosuppressant worldwide.3) TPE, one of 
several immunomodulating techniques, plays an im-
portant role by removing IgG and IgM ABO anti-
body (Ab) in iABO KT.
TPE to permit iABO KT has been successfully 
performed at several centers in Korea and is cur-
rently an American Society for Apheresis Category 
II indication.4) Albumin is the most commonly used 
replacement fluid for TPE. The procedure cost of 
TPE including the charge of albumin as replacement 
fluid is 740,000 Korean won per one exchange in 
Korea. However, only a limited number of plasma 
exchanges is covered by Korean medical insurance.5) 
In the United States, the cost is $5,925 per one ex-
change, only including base inputs without facility 
and side effect costs.6) Although the major adverse ef-
fects of TPE, such as symptomatic hypocalcemia, 
hypotension, urticaria, and nausea, occur in approx-
imately 4% of procedures, long-lasting immuno-
suppression may lead to hazardous clinical con-
sequences, such as persistent lymphopenia, increased 
risk of infection, or viral reactivation.7-9)
A review of our TPE program for iABO KT is 
necessary to determine whether it is efficient and 
reasonable because individual institutions use their 
own innate Ab removal programs. The Johns Hopkins 
group uses a schedule for the number of planned 
pre- and posttransplant TPE treatments based on 
pre-TPE IgG titer based on a goal ABO Ab titer of 
≤16, whereas the Royal Melbourne Hospital group 
uses a goal ABO Ab titer of 8∼32 depending on 
the titration method.10,11)
The substance removal kinetics of TPE is known 
to be exponential based on a several compartment 
models, and post-exchange events with optimal in-
tervals between the procedures have been developed.12) 
The objective of our study was to define the number 
of TPEs according to initial ABO Ab titers to guide 
clinicians in the design of ideal strategies for pa-
tients preparing iABO KT.
Materials and Methods
1. Patients
One hundred seventeen end-stage renal disease 
patients, excluding two outlier patients among 119 
patients, with negative pre-transplant lymphocyte 
cross match test who had undergone iABO KT at 
Severance Hospital between June 2010 and July 
2015 were included in this study. The relationship 
of initial ABO Ab titer and the number of TPEs re-
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Table 1. Distribution of recipient-donor ABO type and ABO antibody titers
Blood group Anti-A or Anti-B titer
No. of cases (%)
Recipient Donor
IgG IgM
Anti-A Anti-B Anti-A Anti-B
O A 4∼512 -  8∼512 -  18 (15.1)*
O AB 32∼128 16∼64 32 16∼64   3 (2.5)
O B -    8∼1,024 -   8∼128  18 (15.1)*
A AB - ≤2∼128 -   4∼256  14 (11.8)
A B - ≤2∼64 -   4∼64  21 (17.6)
B AB ≤2∼64 -  4∼128 -  24 (20.2)
B A 2∼128 -  4∼128 -  21 (17.6)
Total 119 (100.0)
*One outlier patient was included.
quired to reach post-TPE Ab titer to ≤1:8 prior to 
kidney transplantation was retrospectively evaluated 
according to their blood groups and ABO Ab 
classes. Clinical and laboratory data were extracted 
from our electronic database and the patient’s medi-
cal records. 
2. Pre-transplantation conditioning
All patients underwent the pre-transplantation 
conditioning protocol that consists of TPE followed 
by IVIG (100 mg/kg) and immunosuppressants (0.1 
mg/day tacrolimus, 1500 mg/day mycophenolate, 20 
mg/day prednisone, 375 mg/m2 rituximab) administ-
ration. All patients received pre-transplantation con-
ditioning prior to the operation. TPE was conducted 
using the COBE spectra system (Terumo BCT, 
Lakewood, CO, USA) mostly for patients who had 
ABO Ab titers greater than 1:8. One plasma volume 
was removed from each patient and 100% replace-
ment was provided using a 5% albumin solution 
(Green Cross, Yongin, Korea) or fresh frozen plas-
ma (FFP) of the AB blood group. TPE and IVIG 
treatments were conducted every other day before 
transplantation until both IgM and IgG titers were 
no greater than 1:8 in most cases. TPE was per-
formed using 5% albumin solution for the initial ses-
sions, and the last 2 sessions of TPE were carried 
out with the AB blood group FFP to prevent bleed-
ing before transplantation. Immunosuppressive drugs 
were used before transplantation to prevent graft 
rejection. Administration of tacrolimus, mycopheno-
late, and prednisone was initiated 7 days prior to 
transplantation, and rituximab was administered 2 days 
before transplantation after performing TPE.13,14)
3. Measurement of ABO antibody titers
ABO Ab titers were determined by the tube meth-
od, testing two-fold serial dilutions of the patients’ 
serum with commercially available A/B indicator 
red cells using 3.0% Affirmagen (Ortho Clinical 
Diagnostics, Raritan, NJ, USA). After incubation at 
room temperature for 30 min and centrifugation at 
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Fig. 1. Distribution of initial ABO antibody titer of recipients according to blood group. (A) Distribution of 
blood group A recipients, (B) B recipients, and (C) O recipients. The initial ABO Ab titers of blood group 
O recipients were significantly higher in the case of IgG, compared to both blood group A and blood group 
B recipients (P＜0.001), whereas in the case of IgM, only ABO Ab titers of blood group O recipients were 
significantly higher compared to blood group A recipients (P=0.040).
3400 rpm for 15 seconds, the highest serum dilution 
ratio showing 1＋ reactivity by indicated the ABO 
Ab titers was identified. IgG titers were measured 
using serum samples treated with 0.01 M dithio-
threitol solution (Sigma-Aldrich, St. Louis, MO, 
USA), while IgM titers were determined from un-
treated samples.2) Antibody titers were evaluated ev-
ery day after initiation of the conditioning protocol 
while preparing for transplantation. The initial ABO 
Ab variable used in the correlation analysis is defined 
as an IgG, IgM and higher Ab titer between IgG and 
IgM classes before the initiation of Ab depletion. 
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Recipient Donor IgG IgM IgG or IgM
O B, AB Anti-B 0.831* 0.7017 0.8855*
O A, AB Anti-A 0.8414* 0.0581 0.8874*
A B, AB Anti-B 0.6525 0.8484 0.7919
B A, AB Anti-A 0.5044 0.7924 0.65
*The four correlations which showed the best fit in linear relationship.
4. Statistical analysis
The two-sample t-test was used to compare ABO 
Ab titers (log2 initial ABO Ab titer) among the 
blood groups with SPSS software (version 23.0; 
SPSS Inc., Chicago, IL, USA), and a two-tailed val-
ue of P＜0.05 was considered statistically signiﬁ
cant. The value of R2 (coefficient of determination) 
was calculated by using Microsoft Excel 2010 
(Microsoft Corporation, Richmond, WA, USA).
Results
1. Patients
Among the total of 117 patients, 80 patients were 
male (68.4%) and the median age of the patients 
was 46 years (interquartile range 37∼53 years). 
Transplantation from AB donors to B recipients (AB
→B), A→B, and B→A were majority pair combina-
tions including approximately 19.7%, 17.9%, and 
17.1% of the population, respectively, and three cas-
es (2.6%) of AB→O were performed (Table 1). 
2. Initial ABO antibody and TPE
The distribution of initial IgG or IgM ABO Ab 
titer is illustrated according to recipients’ blood 
types (Fig. 1).
The initial ABO Ab titers of blood group O recip-
ients were significantly higher in case of IgG, com-
pared to both blood group A and blood group B re-
cipients (P＜0.001), whereas in case of IgM, ABO 
Ab titers of blood group O recipients were only sig-
nificantly higher compared to blood group A recipi-
ents (P=0.040). 
The average number±standard deviation (range) 
of TPEs performed prior to iABO KT was 3.0±1.1 
(0∼5) in blood group A, 3.7±1.5 (0∼8) in blood 
group B, and 5.3±1.9 (2∼13) in blood group O re-
cipients, respectively. While most transplantations 
proceeded at an ABO Ab titer of 1:8, 11 patients 
(9.4%) with IgG or IgM titers not lower than 1:16 
underwent iABO KT, including nine blood group O 
recipients (five A→O and four B→O cases) and two 
blood group B recipients (one A→B and one AB→
B case).
The correlation between the initial ABO Ab titer 
of IgG, IgM and higher Ab titer between IgG and 
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Fig. 2. Relationship between initial ABO antibody 
titer (Ab) and number of therapeutic plasma 
exchanges (TPEs). The best correlation between the 
initial ABO Ab titer of the higher Ab titer between 
IgG and IgM classes and the number of TPEs 
observed showed a linear relationship (y=0.6829x＋
0.0523, R2=0.946, x=log2 initial ABO Ab titer, 
y=number of TPE required), if all 117 cases were 
integrated regardless of recipient’s blood type or ABO 
Ab classes.
IgM classes and the number of TPEs observed most-
ly showed an exponential relationship (x=log2 initial 
ABO Ab titer, y=number of TPE required), exclud-
ing four circumstances when the recipient was O 
blood type, calculated with IgG and higher Ab titer 
between IgG and IgM classes (Table 2). However, 
the best correlation between the initial ABO Ab titer 
of the higher Ab titer between IgG and IgM classes 
and the number of TPEs observed showed an linear 
relationship (y=0.6829x＋0.0523, R2=0.946, x=log2 
initial ABO Ab titer, y=number of TPE required), 
if all the 117 cases were integrated in regardless of 
recipient’s blood type or ABO Ab classes. This can 
be universally applied in practice, for example, if a 
blood group A recipient had an initial IgG type an-
ti-B with 1:8 and IgM type anti-B with 1:32. The 
x is 5 (the higher value, 1:32 IgM, transformed to 
log base 2) and y, the expected number of TPEs for 
iABO KT, was 3.467 (Fig. 2).
3. Outlier patients
Among the 119 cases, two patients had undergone 
an unexpected number of TPEs, with both patients 
showing initial ABO Ab titers of 1:256. One patient 
was an blood group O 5-year-old boy who was diag-
nosed with Wilms’ tumor, nephrectomy due to renal 
failure aggravated by localized solid mass, and had 
received a kidney from his mother, who was A 
blood type. Immunosuppressant therapy and two 
rounds of TPE by using replacement fluids including 
albumin and FFP, respectively, lowered his titers to 
1:4, with a good response to Ab removal. 
Another patient was an blood group O 64-year-old 
male diagnosed with end-stage renal disease due to 
prolonged hypertension and a history of chronic hep-
atitis C. He received a kidney from his daughter, 
who had a B blood type. Although the pre-con-
ditioning regimen was adopted, his anti-B titer did 
not decrease easily. A total of 13 rounds of TPE 
were performed (9 albumin and 4 FFP episodes) to 
lower his titers to 1:4, conducted by the addition of 
eight TPEs to five TPEs, which were more than ini-
tially planned. 
Discussion
The findings of our retrospective study confirm 
that the number of TPEs required to proceed to 
iABO KT shows an exponential relationship be-
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tween initial ABO Ab, which was previously re-
ported by Lawrence et al.15) Although his study fo-
cused on IgG Ab titer, we considered all aspects in 
IgG, IgM, and either higher Ab titer of IgG or IgM 
classes, because there is currently a debate regarding 
which immunoglobulin class is more potent in the 
course of rejection.16) In addition, we focused on the 
correlation according to the recipients’ blood group 
and ABO Ab titer, which is critical for graft 
survival.17) This is the first study to suggest a num-
ber of TPEs based on the investigation considering 
the recipients’ specific blood types and ABO Ab class.
As TPE removes substances present intravascularly, 
it can be expected that removal efficacy is superior 
in IgM compared to that in IgG or IgA, as the ex-
travascular distribution was found to be 55%, 58%, 
and 22%, respectively.18) The findings of our study 
in cases of recipient blood groups A and B were 
consistent with this principle; however, in cases of 
recipient blood group O, the best correlation was ob-
served when a higher Ab titer of either IgG or IgM 
classes was applied.19) In addition, as ABO IgM iso-
agglutinins exist in a greater amount than IgG, the 
number of TPE may have been affected by this 
cause.20)
Blood group O recipients had higher Ab titers 
than other blood group recipients, especially in IgG 
isoagglutinin; the maximum levels of IgG anti-A and 
anti-B were 1:512 and 1:1024, respectively. This 
finding is consistent with the observations of pre-
vious studies in Korea in that blood group O in-
dividuals generally have high titers against A or B 
blood antigens.21,22)
The use of replacement fluid in TPE differs 
among institutions based on the physiological impact 
of such fluids. FFP, which contains all coagulation 
factors in normal concentrations, can minimize 
bleeding risk prior to operation. In the protocol used 
by the Johns Hopkins Medical Center, FFP compat-
ible with the donor and recipient is used as the last 
portion of the replacement fluids after the use of al-
bumin when the patient is at risk of bleeding.10) FFP 
is associated with a higher risk of hypersensitivity 
reactions and transmission of viral infections with 
the supplementation of coagulation factors; however, 
its use as a replacement fluid is preferred compared 
to albumin in many cases.23)
The strength of this study is that the TPE protocol 
is universally applied among most cases, as AB type 
FFP is used in the two last sessions before trans-
plantation after several TPEs with albumin. There-
fore, the number of TPEs acquired from our equa-
tion can be easily adopted. The clinical importance 
of immunoglobulin classes is unclear; however, our 
approach is safe for preserving good allograft 
outcomes. The Ab titer can be quantified using ad-
vanced methodologies, such as flow cytometry or 
gel techniques, which can provide more accurate 
correlations.24,25)
In conclusion, we suggest that a number of TPEs 
can be highly deduced from initial ABO Ab titers 
regardless of the specific blood type or ABO Ab 
classes; therefore, can contribute to the reduction in 
patients’ side effects as well as financial costs. 
요 약
배경: ABO 부적합 신이식시 탈감작을 위해 시
행하고 있는 치료적 혈장교환술의 효율성과 안전
성에 대한 관심이 증가되고 있다. 본 연구에서는 
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신이식 전 목표 역가에 도달하는데 필요한 ABO 
혈액형별 치료적 혈장교환술의 횟수에 대해 결정
해보고자 하였다.
방법: ABO 부적합 신이식을 받은 117명의 환
자를 대상으로 ABO 항체의 역가 분포를 조사하
였다. 또한 초기 ABO 항체의 역가와 이식전 1:8 
이하의 목표 역가를 달성하기 위한 치료적 혈장
교환술의 횟수를 각 혈액형 및 ABO 항체 종류 
별로 후향적으로 분석하였다.
결과: 초기 ABO 항체의 역가는 O형 혈액형 수
여자의 IgG에서 가장 높은 값을 보였으며, ABO 
부적합 신이식시 치료적 혈장교환술 횟수의 평균
±표준편차(분포)는 A형 3.0±1.1 (0∼5), B형 3.7±1.5 
(0∼8), 및 O형 5.3±1.9 (2∼13) 회의 치료적 혈장
교환술이 시행되었다. 또한 초기 ABO 항체의 역
가와 치료적 혈장교환술의 횟수는 117명의 ABO 
혈액형에 상관없이 모두 취합하여 계산한 경우 
가장 적합한 직선성 관계를 보였다(y=0.6829x＋
0.0523, R2= 0.946, x=log2 초기 ABO 항체 역가, y=
치료적 혈장교환술의 횟수).
결론: 초기 ABO 항체의 역가를 바탕으로 치료
적 혈장교환술의 횟수를 추정할 수 있었으며 향
후 탈감작 프로그램에서의 본 공식은 치료적 혈
장교환술의 효율성 제고와 환자 안전에 기여하는
데 도움을 줄 것으로 판단된다.
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